Brief: Shanghai Bao Pharmaceuticals Says U.S. FDA Approves IND For Subcutaneous Infusion Of BJ007 For Injection
10/06/2026 16:33
BRIEF-Shanghai Bao Pharmaceuticals Says U.S. FDA Approves IND For Subcutaneous Infusion Of BJ007 For Injection June 10 (Reuters) - Shanghai Bao Pharmaceuticals Co Ltd 2659.HK:
U.S. FDA APPROVES IND FOR SUBCUTANEOUS INFUSION OF BJ007 FOR INJECTION ON MAY 27, 2026
Further company coverage: 2659.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Bao Pharmaceuticals Co
See all newsBrief: Shanghai Bao Pharmaceuticals Says U.S. FDA Approves IND For Subcutaneous Infusion Of BJ007 For Injection
Brief: Shanghai Bao Pharmaceuticals Says NMPA Accepts NDA For KJL03 For Injection
Brief: Shanghai Bao Pharmaceuticals Says NMPA Approves Human Hyaluronidase For Injection For Marketing
Shanghai Bao at nearly 4-week high on China regulator nod to new product
Brief: Shanghai Bao Pharmaceuticals Proposes To Elect Liu Yanjun, Wang Zheng, Li Cui As Executive Directors